Status:
COMPLETED
Study to Assess Potential Different Properties of Telmisartan Compared to Candesartan in Healthy Volunteers
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Healthy
Eligibility:
MALE
18-45 years
Phase:
PHASE4
Brief Summary
Study to assess potential different properties of telmisartan, which due to its Vd, should result in stronger "beneficial" effects of AT1 blockade in tissues (e.g. aldosterone suppression and renin in...
Eligibility Criteria
Inclusion
- Males, aged 18 to 45 years.
- Absence of any relevant disease as determined by no clinically deviation from normal in medical history, clinical laboratory determination, ECGs and physical examinations
- Systolic blood pressure (SBP) between 100 and 140 mmHg systolic and below 85 mmHg diastolic (both left and right arm) and a heart rate of ≥50 bpm
- Signed informed consent form
- No intake of drugs inbetween a waiting time of ten times of half-life
Exclusion
- Contraindications to Ang II antagonists, known hypersensitivity, history of angioedema, serious allergy, asthma, allergic skin rash, significant allergic rhinitis or sensitivity to any drug
- History of cardiovascular diseases: any clinically significant cardio-vascular disease, a supine diastolic blood pressure \>86 mmHg and systolic \>141 mmHg measured by a standard sphygmomanometer or a heart rate ≤49 bpm
- Cerebrovascular diseases: history of stroke or transitory ischemic attacks (TIAs) or history of any cerebral bleeding
- Renal diseases: serum creatinine \>1.5 mg/dL
- Gastrointestinal/Hepatic diseases: Aspartate aminotransferase (ASAT) \>40 U/l or Alanine aminotransferase (ALAT) \>40 U/L, serum bilirubin \>2x upper limit of normal, history of malabsorption or inability to tolerate oral medication, history of gastric or duodenal ulcers, history of significant gastrointestinal bleeding, history of hepatitis within the past years
- Any history of alcohol or drug abuse
- Use of any of the following drugs within 4 weeks of study enrolment (e.g. agents known to induce drug metabolizing enzymes): anabolic steroids and corticoids, antiarrhythmics (amiodarone, mexiletine, quinidine, propafenone), antibiotics (chloramphenicol, tetracyclines, sulfonamides, macrolides, cephalosporins, rifampicin, nalidixic acid), antiepileptics (phenytoin, carbamazepine), antifungals (e.g. griseofulvin), barbiturates, cimetidine, ethacrynic acid, fibrates, furosemide, haloperidol, lipid lowering agents (cholestyramine, hydroxymethylglutaryl, coenzyme A (HMG CoA) reductase inhibitors, dextrothyroxin), thyroid replacement therapy hormones or thyrostatics (thioureylene-type). The use of nonsteroidal antiinflammatory drugs (NSAIDs) should be discontinued 2 weeks prior to study enrolment, the one exception of aspirin should be one (1) week prior to study enrolment
- Participation in any other investigational study, within the 30 days prior to enrolment
- Blood donation within the previous 3 months
- The investigator might disqualify a subject for a sound medical or psychiatric reason
Key Trial Info
Start Date :
April 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT02261116
Start Date
April 1 2002
Last Update
October 10 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.